EXINI Diagnostics AB
EXINI: Benefits using BSI highlighted at the annual Japanese Urological Association’s meeting in Kobe, April 24-27, 2014
DGAP-News: EXINI Diagnostics AB / 08.05.2014 / 08:48 --------------------------------------------------------------------- Lund, Sweden, 2014-05-08 08:48 CEST (GLOBE NEWSWIRE) -- Arranged by Fujifilm RI Pharma and with significant EXINI representation, the symposium on April 25, focused on Bone Scan Index (BSI) as a quantitative assessment tool in relation to bone metastases from urologic cancer. Distinguished Professors Nonomura Norio from Osaka University, and Kamai Takao from Dokkyo Medical University chaired the symposium. International BSI-authority, Dr. Michael Morris from Memorial Sloan Kettering Cancer Centre in New York, was invited to comment on the experiences and results presented by the following five keynote speakers: Dr. Uemura Motohide, Osaka University Outline of the bone metastases assessment by BONENAVI Dr. Nozawa Masahiro, Kinki University Assessment of the bone metastases with the bone metabolism marker Dr. Ito Akito, Iwate Medical University Utility and the future prospects of BONENAVI in renal carcinoma bone metastases Dr. Mizokami Atsushi, Kanazawa University Review prostate cancer bone metastases through BONENAVI Dr. Shinohara Nobuo, Hokkaido University Comparison between bone scan and other image assessment 'I am impressed by the outcome and by the attending authorities at this symposium. Fujifilm RI Pharma manages to draw attention to the medical benefits of extracting BSI-value from BONENAVI. This JUA-hosted symposium serves as a good example on how we can spread the knowledge on BSI's importance as an Imaging Biomarker world wide, in relation to both prostatic- and breast cancer.' comments CEO Magnus Aurell. For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 08.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden ISIN: SE0001810284 End of News DGAP News-Service --------------------------------------------------------------------- 267195 08.05.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden